Tongli Zhang

Dr. Tongli Zhang

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
TZTongli Zhang
Tongli Zhang
IAIoannis P. Androulakis
Ioannis P. Androulakis
PBPeter Bonate
Peter Bonate
LCLimei Cheng
Limei Cheng
JPJaimit Parikh
Jaimit Parikh
ESEric Sobie
Eric Sobie
Quantitative systems pharmacology (QSP) modeling is applied to address essential questions in drug development, such as the mechanism of action of a therapeutic agent and the progression of disease. Meanwhile, machine learning (ML) approaches also contribute to answering these questions via the analysis of multi-layer ‘omics’ data such as gene expression, proteomics, metabolomics, and high-throughput imaging. Furthermore, ML approaches can also be applied to aspects of QSP modeling. Both approaches are powerful tools and there is considerable interest in integrating QSP modeling and ML. So far, a few successful implementations have been carried out from which we have learned about how each approach can overcome unique limitations of the other. The QSP + ML working group of the International Society of Pharmacometrics QSP Special Interest Group was convened in September, 2019 to identify and begin realizing new opportunities in QSP and ML integration. The working group, which comprises 21 members representing 18 academic and industry organizations, has identified four categories of current research activity which will be described herein together with case studies of applications to drug development decision making. The working group also concluded that the integration of QSP and ML is still in its early stages of moving from evaluating available technical tools to building case studies. This paper reports on this fast-moving field and serves as a foundation for future codification of best practices.

14 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RBRichard Ballweg
Richard Ballweg
APAndrew L. Paek
Andrew L. Paek
TZTongli Zhang
Tongli Zhang
When chemotherapy drugs are applied to tumor cells with the same or similar genotypes, some cells are killed, while others survive. This fractional killing contributes to drug resistance in cancer. Through an incoherent feedforward loop, chemotherapy drugs not only activate p53 to induce cell death, but also promote the expression of apoptosis inhibitors which inhibit cell death. Consequently, cells in which p53 is activated early undergo apoptosis while cells in which p53 is activated late survive. The incoherent feedforward loop and the essential role of p53 activation timing makes fractional killing a complex dynamical challenge, which is hard to understand with intuition alone. To better understand this process, we have constructed a representative model by integrating the control of apoptosis with the relevant signaling pathways. After the model was trained to recapture the observed properties of fractional killing, it was analyzed with nonlinear dynamical tools. The analysis suggested a simple dynamical framework for fractional killing, which predicts that cell fate can be altered in three possible ways: alteration of bifurcation geometry, alteration of cell trajectories, or both. These predicted categories can explain existing strategies known to combat fractional killing and facilitate the design of novel strategies.

26 April 2022 in Cells
Verified
Journal Article
Open access
PDF file
TTTomoyuki Tanaka
Tomoyuki Tanaka
TZTongli Zhang
Tongli Zhang
For correct chromosome segregation in mitosis, eukaryotic cells must establish chromosome biorientation where sister kinetochores attach to microtubules extending from opposite spindle poles. To establish biorientation, any aberrant kinetochore–microtubule interactions must be resolved in the process called error correction. For resolution of the aberrant interactions in error correction, kinetochore–microtubule interactions must be exchanged until biorientation is formed (the SWAP process). At initiation of biorientation, the state of weak kinetochore–microtubule interactions should be converted to the state of stable interactions (the SWITCH process)—the conundrum of this conversion is called the initiation problem of biorientation. Once biorientation is established, tension is applied on kinetochore–microtubule interactions, which stabilizes the interactions (the STABILIZE process). Aurora B kinase plays central roles in promoting error correction, and Mps1 kinase and Stu2 microtubule polymerase also play important roles. In this article, we review mechanisms of error correction by considering the SWAP, SWITCH, and STABILIZE processes. We mainly focus on mechanisms found in budding yeast, where only one microtubule attaches to a single kinetochore at biorientation, making the error correction mechanisms relatively simpler.

15 September 2025 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
JSJennifer Sheng
Jennifer Sheng
TZTongli Zhang
Tongli Zhang
Model-informed Drug Development (MIDD) is an essential framework for advancing drug development and supporting regulatory decision-making. The current review presents a strategic blueprint to closely align MIDD tools with key questions of interests (QOI), content of use (COU), and model impact across stages of development —from early discovery to post-market lifecycle management. To demonstrate how the strategy works, we have also provided examples of how the MIDD tools can be applied to enhance the target identification, assist with lead compound optimization, improve preclinical prediction accuracy, facilitate First-in-Human (FIH) studies, optimize clinical trial design including dosage optimization, describe clinical population pharmacokinetics/exposure-response (PPK/ER) characteristics, and support label updates during post-approval stages. Additionally, the roles of some commonly used modeling methodologies, such as quantitative structure-activity relationship (QSAR), physiologically based pharmacokinetic (PBPK), semi-mechanistic pharmacokinetics/pharmacodynamics (PK/PD), PPK/ER, and quantitative systems pharmacology (QSP), are highlighted. What is more, we also explored the evolving role of MIDD in the context of emerging technologies, such as artificial intelligence (AI) and machine learning (ML) approaches. Further, MIDD utilities in development and regulatory evaluation of 505(b) (2) and generic drug products, as well as practical considerations of MIDD in regulatory interactions and asset acquisitions, are briefly discussed. At the end of the review, we briefly addressed the potential challenges faced by MIDD, such as lack of appropriate resources and slow organizational acceptance and alignment, as well as our perspectives on future opportunities of how MIDD could be further expanded.

17 July 2018 in BMC Systems Biology
Verified
Journal Article
Open access
PDF file
GLGuan-Sheng Liu
Guan-Sheng Liu
RBRichard Ballweg
Richard Ballweg
AAAlan Ashbaugh
Alan Ashbaugh
YZYin Zhang
Yin Zhang
JFJoseph Facciolo
Joseph Facciolo
TZTongli Zhang
Tongli Zhang
The yeast-like fungi Pneumocystis, resides in lung alveoli and can cause a lethal infection known as Pneumocystis pneumonia (PCP) in hosts with impaired immune systems. Current therapies for PCP, such as trimethoprim-sulfamethoxazole (TMP-SMX), suffer from significant treatment failures and a multitude of serious side effects. Novel therapeutic approaches (i.e. newly developed drugs or novel combinations of available drugs) are needed to treat this potentially lethal opportunistic infection. Quantitative Systems Pharmacological (QSP) models promise to aid in the development of novel therapies by integrating available pharmacokinetic (PK) and pharmacodynamic (PD) knowledge to predict the effects of new treatment regimens. In this work, we constructed and independently validated PK modules of a number of drugs with available pharmacokinetic data. Characterized by simple structures and well constrained parameters, these PK modules could serve as a convenient tool to summarize and predict pharmacokinetic profiles. With the currently accepted hypotheses on the life stages of Pneumocystis, we also constructed a PD module to describe the proliferation, transformation, and death of Pneumocystis. By integrating the PK module and the PD module, the QSP model was constrained with observed levels of asci and trophic forms following treatments with multiple drugs. Furthermore, the temporal dynamics of the QSP model were validated with corresponding data. We developed and validated a QSP model that integrates available data and promises to facilitate the design of future therapies against PCP.

9 September 2019 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
YZYin Zhang
Yin Zhang
JHJulie M Huynh
Julie M Huynh
GLGuan-Sheng Liu
Guan-Sheng Liu
RBRichard Ballweg
Richard Ballweg
KAKayenat S Aryeh
Kayenat S Aryeh
TZTongli Zhang
Tongli Zhang
Chemotherapy resistance is a major challenge to the effective treatment of cancer. Thus, a systematic pipeline for the efficient identification of effective combination treatments could bring huge biomedical benefit. In order to facilitate rational design of combination therapies, we developed a comprehensive computational model that incorporates the available biological knowledge and relevant experimental data on the life-and-death response of individual cancer cells to cisplatin or cisplatin combined with the TNF-related apoptosis-inducing ligand (TRAIL). The model’s predictions, that a combination treatment of cisplatin and TRAIL would enhance cancer cell death and exhibit a “two-wave killing” temporal pattern, was validated by measuring the dynamics of p53 accumulation, cell fate, and cell death in single cells. The validated model was then subjected to a systematic analysis with an ensemble of diverse machine learning methods. Though each method is characterized by a different algorithm, they collectively identified several molecular players that can sensitize tumor cells to cisplatin-induced apoptosis (sensitizers). The identified sensitizers are consistent with previous experimental observations. Overall, we have illustrated that machine learning analysis of an experimentally validated mechanistic model can convert our available knowledge into the identity of biologically meaningful sensitizers. This knowledge can then be leveraged to design treatment strategies that could improve the efficacy of chemotherapy. Combination chemotherapy is frequently used in the fight against cancer as treatment with multiple chemotherapy drugs of different molecular mechanisms reduces the chance of resistance. The complex mechanisms involved makes it essential to develop a comprehensive computational model that comprehends experimental data and biological knowledge to facilitate design of combination therapies. As computational models grow and capture more and more molecular events governing the chemotherapy response, it becomes harder to explore the treatment space efficiently and systematically. To facilitate the extraction of unbiased solutions from complicated models, we have conducted systematic analysis using a series of machine learning methods including Partial Least Squares regression (PLS), Random forest (RF), Logistic Regression (LR) and Support Vector Machine (SVM). The results of these different methods were cross-validated to reduce the chance of overfitting or bias by any single method. Overall, we propose a novel computational pipeline, where machine learning analysis of experimentally validated models is used to generate unbiased predictions of novel chemotherapy targets.